購(gòu)物車
幫助
021-54845833/15800441009
儲(chǔ) 存： 冷凍（-20℃） 避光
技術(shù)規(guī)格
|
Background: |
INDO/IDO1/indoleamine 2,3-dioxygenase (IDO) is an IFN-γ-inducible enzyme that catalyzes the rate-limiting step of tryptophan degradation. IDO is upregulated in many tumors and in dendritic cells in tumor-draining lymph nodes. Elevated tryptophan catabolism in these cells leads to tryptophan starvation of T cells, limiting T cell proliferation and activation. Therefore, IDO is considered an immunosuppresive molecule, and research studies have shown that upregulation of IDO is a mechanism of cancer immune evasion. The gastrointestinal stromal tumor drug, imatinib, was found to act, in part, by reducing IDO expression, resulting in increased CD8+ T cell activation and induction of apoptosis in regulatory T cells. In addition to its enzymatic activity, IDO was recently shown to have signaling capability through an immunoreceptor tyrosine-based inhibitory motif (ITIM) that is phosphorylated by Fyn in response to TGF-β. This leads to recruitment of SHP-1 and activatation of the noncanonical NF-κB pathway. |
|
Applications: |
WB |
|
Name of antibody: |
INDO |
|
Immunogen: |
Fusion protein of human INDO |
|
Full name: |
indoleamine 2,3-dioxygenase 1 |
|
Synonyms： |
CD107B; IDO; INDO |
|
SwissProt: |
P14902 |
|
WB Predicted band size: |
45 kDa |
|
WB Positive control: |
Placenta tissue |
|
WB Recommended dilution: |
500-2000 |
